• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Quotient Limited

    6/26/23 5:01:10 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QTNT alert in real time by email
    S-8 POS 1 qtntq20230626l_s8pos.htm FORM S-8 POS qtntq20230626l_s8pos.htm

     

     

    As filed with the Securities and Exchange Commission on June 26, 2023

     

    Registration No. 333-265945

    Registration No. 333-262376

    Registration No. 333-261179

    Registration No. 333-259926

    Registration No. 333-259208

    Registration No. 333-258307

    Registration No. 333-256901

    Registration No. 333-254866

    Registration No. 333-249947

    Registration No. 333-249946

    Registration No. 333-239432

    Registration No. 333-236295

    Registration No. 333-232016

    Registration No. 333-228330

    Registration No. 333-225553

    Registration No. 333-218462

    Registration No. 333-214483

    Registration No. 333-195507

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-265945

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-262376

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-261179

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-259926

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-259208

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-258307

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-256901

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-254866

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-249947

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-249946 

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-239432

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-236295

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.               333-232016

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-228330

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-225553

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-218462

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.               333-214483

    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No.              333-195507

     

     

     

    FORM S-8 POS

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    QUOTIENT LIMITED

    (Exact name of registrant as specified in its charter)

     

     

     

    Jersey, Channel Islands

    Not Applicable

    (State or other jurisdiction of incorporation or organization)

    (I.R.S. Employer Identification Number)

       
       

    001-36415

    (Commission File Number)

     

    Business Park Terre Bonne,

    Route de Crassier 13,

    1262 Eysins, Switzerland

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Not applicable

    (Zip Code)

    Registrant's telephone number, including area code: 011-41-22-716-9800

     

     

     

    n/a
    (Former name or former address, if changed since last report)

     

     

     

    Non-Plan Inducement Share Option Award

    Non-Plan Inducement Restricted Share Unit Award

    Non-Plan Inducement Performance-Based Restricted Share Unit Award

    Quotient Limited 2014 Stock Incentive Plan, as adopted on March 31, 2014, amended and restated on October 28, 2016, further amended and restated on October 31, 2018, and further amended and restated on October 29, 2020

    2013 Enterprise Management Plan

    (Full titles of the plans)

     

     

     

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

    Large accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☒

     

    Smaller reporting company

     

    ☒

           

    Emerging growth company

     

    ☐

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

         

     

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    These Post-Effective Amendments relate to the following Registration Statements on Form S-8 (the “Registration Statements”) filed by Quotient Limited (the “Registrant” or the “Company”) with the Securities and Exchange Commission (the “SEC”):

     

     

    1.

    Registration File No.333-265945, originally filed with the SEC on June 30, 2022, registering (a) 769,585 ordinary shares of no par value of the Registrant (the “Ordinary Shares”) that were automatically added to the number of shares authorized for issuance under the Quotient Limited 2014 Stock Incentive Plan, as adopted on March 31, 2014, amended and restated on October 28, 2016, further amended and restated on October 31, 2018, and further amended and restated on October 29, 2020 (the “Amended and Restated 2014 Plan”), and (b) Ordinary Shares that may be issued upon the vesting of the following awards (issued outside of the Registrant’s Amended and Restated 2014 Plan) to a newly hired individual: up to (i) 112,780 performance-based restricted share units (the “PSUs”); (ii) 67,668 restricted share units (the “RSUs”); and (iii) 45,112 share options (the “Options” and, together with the PSUs and the RSUs, the “Awards”).

     

     

    2.

    Registration File No.333-262376, originally filed with the SEC on January 27, 2022, registering Ordinary Shares that may be issued upon the vesting of the following Awards (issued outside of the Registrant’s Amended and Restated 2014 Plan) to a newly hired individual: up to (a) 290,000 PSUs; (b) 175,000 RSUs; and (c) 175,000 Options.

     

     

    3.

    Registration File No.333-261179, originally filed with the SEC on November 18, 2021, registering Ordinary Shares that may be issued upon the vesting of the following Awards (issued outside of the Registrant’s Amended and Restated 2014 Plan) to a newly hired individual: up to (a) 341,829 PSUs; (b) 205,097 RSUs; and (c) 205,097 Options.

     

     

    4.

    Registration File No.333-259926, originally filed with the SEC on September 30, 2021, registering Ordinary Shares that may be issued upon the vesting of the following Awards (issued outside of the Registrant’s Amended and Restated 2014 Plan) to a newly hired individual: up to (a) 590,000 RSUs; and (b) 460,000 Options.

     

     

    5.

    Registration File No.333-259208, originally filed with the SEC on August 31, 2021, registering Ordinary Shares that may be issued upon the vesting of the following separate Awards (issued outside of the Registrant’s Amended and Restated 2014 Plan) to two newly hired individuals:(a) one Award consisting of up to (i) 110,993 performance share units upon the achievement of specified performance criteria; (ii) 64,259 RSUs; and (iii) 64,259 Options; and (b) one Award consisting of up to (i) 364,007 performance share units upon the achievement of specified performance criteria; (ii) 210,741 RSUs; and (iii) 210,741 Options.

     

     

    6.

    Registration File No.333-258307, originally filed with the SEC on July 30, 2021, registering Ordinary Shares that may be issued upon the vesting of the following Awards (issued outside of the Registrant’s Amended and Restated 2014 Plan) to a newly hired individual: (i) up to 240,000 performance share units upon the achievement of specified performance criteria; (ii) 150,000 RSUs; and (iii) 150,000 Options.

     

     

    7.

    Registration File No.333-256901, originally filed with the SEC on June 8, 2021, registering 759,483 Ordinary Shares for issuance under the Amended and Restated 2014 Plan

     

     

    8.

    Registration File No.333-254866, originally filed with the SEC on March 30, 2021, registering Ordinary Shares that may be issued upon the following: (a) the vesting and settlement of restricted share units having a grant date fair value of $3,333,333 and the exercise of share options having a grant date fair value of $1,666,667; and (b) the vesting and settlement of restricted share units having a grant date fair value of $600,000 and performance-based restricted share units having a grant date fair value of $1,000,000, and the exercise of share options having a grant date fair value of $400,000.

     

     

    9.

    Registration File No.333-249947, originally filed with the SEC on November 6, 2020, registering 750,000 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

     

    10.

    Registration File No.333-249946, originally filed with the SEC on November 6, 2020, registering an aggregate of 41,580 Ordinary Shares that may be issued (outside of the Registrant’s Amended and Restated 2014 Plan) to two individuals upon the exercise of certain share options.  

     

     

    11.

    Registration File No.333-239432, originally filed with the SEC on June 25, 2020, registering 200,000 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

     

    12.

    Registration File No.333-236295, originally filed with the SEC on February 6, 2020, registering an aggregate of 75,000 Ordinary Shares that may be issued (outside of the Registrant’s Amended and Restated 2014 Plan) upon the vesting and settlement of 50,000 RSUs and the exercise of 25,000 Share Options.

     

     

    13.

    Registration File No. 333-232016, originally filed with the SEC on June 7, 2019, registering 200,000 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

     

    14.

    Registration File No.333-228330, originally filed with the SEC on November 9, 2018, registering 550,000 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

     

    15.

    Registration File No.333-225553, originally filed with the SEC on June 11, 2018, registering 200,000 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

     

    16.

    Registration File No.333-218462, originally filed with the SEC on June 2, 2017, registering 200,000 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

     

    17.

    Registration File No. 333-214483, originally filed with the SEC on November 7, 2016, registering 1,120,205 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

     

    18.

    Registration File No.333-195507, originally filed with the SEC on April 25, 2014, registering (a) 779,462 Ordinary Shares issuable upon the exercise of outstanding options granted under the 2013 Enterprise Management Plan and (b) 1,500,000 Ordinary Shares for issuance under the Amended and Restated 2014 Plan.

     

    On January 10, 2023 (the “Petition Date”), the Company filed the Prepackaged Chapter 11 Plan of Reorganization of Quotient Limited (as amended, modified or supplemented from time to time, the “Plan”) and the related disclosure statement (the “Disclosure Statement”) in the United States Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”). On February 15, 2023, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the Plan, as modified by the Confirmation Order, and approving the Disclosure Statement. The Plan is attached to the Confirmation Order as Exhibit A. On February 16, 2023, the Plan became effective in accordance with its terms and the Company emerged from bankruptcy.

     

    Pursuant to the Plan, on March 2, 2023, the Company entered into a Merger Implementation Agreement by and among the Company, Quotient Holdings Merger Company Limited (“MergerCo”) and Quotient Holdings Finance Company Limited (“Finance Co”) (as amended from time to time, the “Merger Implementation Agreement”), pursuant to which, on June 9, 2023 (the “Closing Date”), the Company merged with MergerCo (the “Merger”).

     

    In furtherance of the Merger, the Registrant terminated all offerings of its securities pursuant to the Registration Statements and the Registrant hereby removes and withdraws from registration any and all securities of the Registrant registered pursuant to the Registration Statements that remain unsold or otherwise unissued as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statements.

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York on June 26, 2023.

     

     

     

     

    QUOTIENT LIMITED

     
           
     

    By:

    /s/ Manuel O. Méndez

     
       

    Manuel O. Méndez

     
       

    Chief Executive Officer

     

     

     

     

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the specified registration statements on Form S-8.

     
    Get the next $QTNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QTNT

    DatePrice TargetRatingAnalyst
    12/3/2021$4.00 → $3.50Neutral
    Goldman Sachs
    8/6/2021$5.00 → $4.50Neutral
    Goldman Sachs
    More analyst ratings

    $QTNT
    SEC Filings

    View All

    SEC Form 15-12G filed by Quotient Limited

    15-12G - Quotient Ltd (0001596946) (Filer)

    6/30/23 7:56:39 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Quotient Limited

    EFFECT - Quotient Ltd (0001596946) (Filer)

    6/30/23 12:15:07 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form EFFECT filed by Quotient Limited

    EFFECT - Quotient Ltd (0001596946) (Filer)

    6/30/23 12:15:20 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman Sachs reiterated coverage on Quotient with a new price target

    Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

    12/3/21 9:07:16 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Goldman Sachs reiterated coverage on Quotient with a new price target

    Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $4.50 from $5.00 previously

    8/6/21 8:50:59 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Goldman Sachs initiated coverage on Quotient with a new price target

    Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00

    6/3/21 6:30:51 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QTNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market

    JERSEY, Channel Islands, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to implement the delisting, the Company intends to file a Form 25 with the Securities and Exchange Commission (the "SEC") on or about December 27, 2022. The delisting of the Company's ordinary shares will take effect no earlier than ten days after the date of that Form 25 filing. The Company expects that as a result of this voluntary delisting, the last trading day of its ordinary shares on the Nasda

    12/12/22 4:05:00 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quotient Limited Announces Reverse Stock Split Effective Today

    JERSEY, Channel Islands, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of trading on the Nasdaq Global Market today. The Company's Ordinary Shares will begin trading on a split-adjusted basis when the market opens on November 3, 2022 under the existing trading symbol, "QTNT." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Global Market. The new CUSIP

    11/2/22 5:01:00 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quotient Limited Announces Intent to Effect Reverse Stock Split

    JERSEY, Channel Islands, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that will become effective on November 2, 2022 at 5:01 p.m. Eastern Time, after the close of trading on The Nasdaq Global Market ("Nasdaq"). The Company's Ordinary Shares are expected to begin trading on a split-adjusted basis when the market opens on November 3, 2022 on the Nasdaq under the existing symbol "QTNT." The Reverse Stock Split is primarily intended to bring the Company into compliance

    10/31/22 6:30:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Quotient Holdings Gp, Llc claimed ownership of 17,020,000 shares

    3 - Quotient Ltd (0001596946) (Issuer)

    2/27/23 4:51:06 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3: New insider Highbridge Capital Management Llc claimed ownership of 17,247,931 units of Ordinary Shares

    3 - Quotient Ltd (0001596946) (Issuer)

    2/27/23 4:05:35 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4: Hallsworth Frederick converted options into 438 units of Ordinary Shares, increasing direct ownership by 8% to 6,186 units

    4 - Quotient Ltd (0001596946) (Issuer)

    2/2/23 8:30:35 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QTNT
    Leadership Updates

    Live Leadership Updates

    View All

    Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO

    Sannova Analytical, LLC ("Sannova"), a leading contract research organization ("CRO") that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer. Mr. Apter is an accomplished life sciences executive with outstanding leadership experience and an impressive record of success growing and improving the market position and performance of multiple companies. Most recently, he was the Sector Chief Executive of Johnson Matthey's Health Division. Previously, Jason held leadership positions at Millipore Sigma and the predecessor Sigma-Aldrich. In addition, Sanno

    10/26/22 7:05:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quotient Limited Announces Appointment of New Board Member

    JERSEY, Channel Islands, April 26, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee. "We are delighted to welcome Mr. Aebischer to the Quotient Board," said Heino von Prondzynski, Chairman of Quotient's Board of Directors. "Thomas brings decades of experience in global financial and capital markets and a highly strategic mindset. We are very fortunate to have him by our side as we continue to grow our business and drive the value of our revolutionary diagnostic solutions.

    4/26/22 8:30:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quotient Limited Announces Appointment of Chief Manufacturing Operations Officer

    JERSEY, Channel Islands, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company's Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022. "It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company's evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from the development phase into commercialization, we will drive scale up in manufacturing to transform the business," said Manuel O. Mé

    11/30/21 8:30:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QTNT
    Financials

    Live finance-specific insights

    View All

    Quotient Limited Provides First Quarter Fiscal 2023 Results and Business Update

    MosaiQ™ Solution Commercial Execution: Extended IH Launch: $1.4 million MosaiQ bookings completed with $0.4 million in revenue in the first quarterDistribution Network: Ten agreements signed with more in process; First distributor network meeting held in Switzerland with 12 participantsTenders: The Company continues to actively participate in and prepare for all available tenders Transfusion Diagnostics: Extended Immunohematology (IH) microarray on track for US FDA submission by year-end; Extended Serological Disease Screening (SDS) microarray panel on-track for EU commercial launch in calendar year 2023; InfYnity partnership enriches infectious disease immunoassay microarray offeringClinica

    8/9/22 7:00:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th

    JERSEY, Channel Islands, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient First Quarter Fiscal 2023 Financial Results and Conference Call Speakers:Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief Financial OfficerDate:Tuesday, August 9, 2022Time:8:30am ET/ 14:30 CETConference Call Dial-in Details:International: 201-689-8560Switzerland: 0800 835 525United Kingdom: 0800 756 3429US: 877-407-0784Conference ID: 13731396Webcast:Webcast Link - Click HereQuot

    8/2/22 4:05:00 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update

    Financial Position Amended Secured Notes: Reduces the company's cash obligations by approximately $93 million over the next 36 monthsAnnounces Public Equity Offering: Improving liquidity runwayFY 2022 Revenue of $38.5 Million$83.2 million in cash and investments as of March 31, 2022  MosaiQ™ Solution Commercial Execution: Extended IH Launch: Commercialization is underway; $1.4 million of MosaiQ orders in Q1 FY2023; Multiple MosaiQ instruments shipped to customersTenders: Actively engaged in Immunohematology (IH) donor tenders; 20 European IH donor tender submissions expected in the next 18 monthsDistribution Network: 9 international agreements in place and expanding global distribution ne

    6/24/22 7:00:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Quotient Limited

    SC 13D - Quotient Ltd (0001596946) (Subject)

    2/27/23 4:14:00 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D/A filed by Quotient Limited (Amendment)

    SC 13D/A - Quotient Ltd (0001596946) (Subject)

    2/22/23 10:45:07 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D/A filed by Quotient Limited (Amendment)

    SC 13D/A - Quotient Ltd (0001596946) (Subject)

    2/21/23 5:03:18 PM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care